<DOC>
	<DOCNO>NCT00054431</DOCNO>
	<brief_summary>This phase II trial study well give imatinib mesylate together decitabine work treat patient accelerate blast phase chronic myelogenous leukemia . Imatinib mesylate may stop growth cancer cell block enzymes necessary cancer cell growth . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Giving imatinib mesylate together decitabine may kill cancer cell</brief_summary>
	<brief_title>Imatinib Mesylate Decitabine Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine duration response response rate patient accelerate blastic phase chronic myelogenous leukemia treat imatinib mesylate decitabine . II . Determine survival rate patient treat regimen . III . Determine toxicity regimen patient . IV . Determine effect regimen gene methylation leukemic cell patient . OUTLINE : Patients stratify accord prior exposure imatinib mesylate ( yes v ) . Patients receive oral imatinib mesylate daily decitabine IV 1 hour daily , 5 day per week , 2 consecutive week . Courses repeat every 4-6 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 20-80 patient ( 10-40 per stratum ) accrue study within 20 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Histologically confirm chronic myelogenous leukemia Philadelphia chromosome positive cytogenetics OR fluorescent situ hybridization Accelerated nonlymphoid blastic phase Performance status ECOG 02 Bilirubin great 2 time upper limit normal ( ULN ) AST great 2 time ULN Creatinine le 2.0 mg/dL Normal cardiac function No New York Heart Association class III IV heart disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior decitabine At least 2 week since prior chemotherapy ( unless evidence rapidly progressive disease ) recover Concurrent hydroxyurea allow first 2 course study therapy patient rapidly progress disease Prior imatinib mesylate allow Patients receive least 4 week prior imatinib mesylate must fail therapy , evidence resistance 8 week disease progression No concurrent grapefruit grapefruit juice</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>